175 related articles for article (PubMed ID: 24247248)
1. The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis.
Farrand L; Kim JY; Byun S; Im-aram A; Lee J; Suh JY; Lee KW; Lee HJ; Tsang BK
J Biol Chem; 2014 Jan; 289(3):1723-31. PubMed ID: 24247248
[TBL] [Abstract][Full Text] [Related]
2. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission.
Farrand L; Byun S; Kim JY; Im-Aram A; Lee J; Lim S; Lee KW; Suh JY; Lee HJ; Tsang BK
J Biol Chem; 2013 Aug; 288(33):23740-50. PubMed ID: 23833193
[TBL] [Abstract][Full Text] [Related]
3. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.
Woo MG; Xue K; Liu J; McBride H; Tsang BK
J Biol Chem; 2012 Feb; 287(6):3963-75. PubMed ID: 22117079
[TBL] [Abstract][Full Text] [Related]
4. Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway.
Lee CS; Jang ER; Kim YJ; Myung SC; Kim W; Lee MW
Invest New Drugs; 2012 Apr; 30(2):548-57. PubMed ID: 21120579
[TBL] [Abstract][Full Text] [Related]
5. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
6. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
[TBL] [Abstract][Full Text] [Related]
7. Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt.
Yang X; Fraser M; Abedini MR; Bai T; Tsang BK
Br J Cancer; 2008 Feb; 98(4):803-8. PubMed ID: 18283299
[TBL] [Abstract][Full Text] [Related]
8. p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.
Kong B; Wang Q; Fung E; Xue K; Tsang BK
J Biol Chem; 2014 Sep; 289(39):27134-27145. PubMed ID: 25112877
[TBL] [Abstract][Full Text] [Related]
9.
Seonu SY; Kim MJ; Yin J; Lee MW
Molecules; 2021 Jun; 26(13):. PubMed ID: 34201712
[No Abstract] [Full Text] [Related]
10. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
12. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
Abedini MR; Muller EJ; Bergeron R; Gray DA; Tsang BK
Oncogene; 2010 Jan; 29(1):11-25. PubMed ID: 19802016
[TBL] [Abstract][Full Text] [Related]
13. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
14. Hirsutenone in Alnus extract inhibits akt activity and suppresses prostate cancer cell proliferation.
Kang S; Kim JE; Li Y; Jung SK; Song NR; Thimmegowda NR; Kim BY; Lee HJ; Bode AM; Dong Z; Lee KW
Mol Carcinog; 2015 Nov; 54(11):1354-62. PubMed ID: 25213146
[TBL] [Abstract][Full Text] [Related]
15. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
17. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.
Mir R; Stanzani E; Martinez-Soler F; Villanueva A; Vidal A; Condom E; Ponce J; Gil J; Tortosa A; Giménez-Bonafé P
Gynecol Oncol; 2014 Jan; 132(1):211-20. PubMed ID: 24262875
[TBL] [Abstract][Full Text] [Related]
18. Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.
Hu W; Wang F; Tang J; Liu X; Yuan Z; Nie C; Wei Y
J Biol Chem; 2012 Jan; 287(1):68-80. PubMed ID: 22052903
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.
Mansouri A; Zhang Q; Ridgway LD; Tian L; Claret FX
Oncol Res; 2003; 13(6-10):399-404. PubMed ID: 12725530
[TBL] [Abstract][Full Text] [Related]
20. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]